Skip to content

Study · Not a test of the peptide alone · 2020

8 results

Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Basal Insulin and Basal-Bolus Therapy in Patients with Type 2 Diabetes Based on Attainment of Clinically Relevant Treatment Targets.

Cannon AJ, Bargiota A, Billings L, Hunt B, Leiter LA, Malkin S, Mocarski M, Ranthe MF, Schiffman A, Doshi A

Journal of managed care & specialty pharmacy19 Dec 2019Cited by 4 (Europe PMC)

PMID31856636 (opens in a new tab)PMCIDPMC10391176 (opens in a new tab)DOI10.18553/jmcp.2019.19035 (opens in a new tab)PepBankPUB-31856636
Source linkPubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone8

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 01HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, more patients on the fixed-dose combination IDegLira reached HbA1c <7.5% than on insulin glargine U100.

    In plain wordsIn adults with type 2 diabetes, more people on the insulin degludec/liraglutide combination reached an HbA1c below 7.5% than on insulin glargine.

    Peptide
    Liraglutide
    Outcome
    IncreasePatients reaching HbA1c <7.5%
    Study

    n: not reported in source

    Comparator
    Insulin glargine U100 (DUAL V)
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    More patients achieved HbA1c P < 0.0001)
    1 context sentence
    Summary · context
    This is a post hoc analysis of the DUAL V and DUAL VII 26-week trials, which randomized patients with T2D uncontrolled (HbA1c 7%-10%) on insulin glargine 100 units/mL (IGlar U100) and metformin to IDegLira or continued IGlar U100 titration (DUAL V) or IGlar U100 + insulin aspart (DUAL VII), all with metformin.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 02HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, more patients on the fixed-dose combination IDegLira reached HbA1c <8.0% than on insulin glargine U100.

    In plain wordsIn adults with type 2 diabetes, more people on the insulin degludec/liraglutide combination reached an HbA1c below 8.0% than on insulin glargine.

    Peptide
    Liraglutide
    Outcome
    IncreasePatients reaching HbA1c <8.0%
    Study

    n: not reported in source

    Comparator
    Insulin glargine U100 (DUAL V)
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    and P = 0.0003)
    1 context sentence
    Summary · context
    This is a post hoc analysis of the DUAL V and DUAL VII 26-week trials, which randomized patients with T2D uncontrolled (HbA1c 7%-10%) on insulin glargine 100 units/mL (IGlar U100) and metformin to IDegLira or continued IGlar U100 titration (DUAL V) or IGlar U100 + insulin aspart (DUAL VII), all with metformin.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  3. 03HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, a similar percentage of patients reached HbA1c <=9.0% with the fixed-dose combination IDegLira and with insulin glargine U100.

    In plain wordsIn adults with type 2 diabetes, a similar share reached HbA1c of 9.0% or lower on the insulin degludec/liraglutide combination and on insulin glargine.

    Peptide
    Liraglutide
    Outcome
    No significant changePatients reaching HbA1c <=9.0%
    Study

    n: not reported in source

    Comparator
    Insulin glargine U100 (DUAL V)
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    and a similar percentage achieved HbA1c ≤ 9.0% with IDegLira versus IGlar U100 (DUAL V).
    1 context sentence
    Summary · context
    This is a post hoc analysis of the DUAL V and DUAL VII 26-week trials, which randomized patients with T2D uncontrolled (HbA1c 7%-10%) on insulin glargine 100 units/mL (IGlar U100) and metformin to IDegLira or continued IGlar U100 titration (DUAL V) or IGlar U100 + insulin aspart (DUAL VII), all with metformin.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  4. 04HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, similar proportions of patients reached all three HbA1c targets with the fixed-dose combination IDegLira and with basal-bolus therapy.

    In plain wordsIn adults with type 2 diabetes, similar shares of people reached all three HbA1c targets on the insulin degludec/liraglutide combination and on basal-bolus insulin.

    Peptide
    Liraglutide
    Outcome
    No significant changePatients reaching HbA1c targets <7.5%, <8.0% and <=9.0%
    Study

    n: not reported in source

    Comparator
    Basal-bolus therapy (DUAL VII)
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    Similar proportions of patients achieved all 3 HbA1c targets with IDegLira compared with basal-bolus therapy (DUAL VII).
    1 context sentence
    Summary · context
    This is a post hoc analysis of the DUAL V and DUAL VII 26-week trials, which randomized patients with T2D uncontrolled (HbA1c 7%-10%) on insulin glargine 100 units/mL (IGlar U100) and metformin to IDegLira or continued IGlar U100 titration (DUAL V) or IGlar U100 + insulin aspart (DUAL VII), all with metformin.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  5. 05HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, the odds of reaching HbA1c targets without hypoglycaemia or weight gain were significantly higher with the fixed-dose combination IDegLira than with insulin glargine U100.

    In plain wordsIn adults with type 2 diabetes, insulin degludec/liraglutide gave higher odds than insulin glargine of reaching HbA1c targets without low sugar or weight gain.

    Peptide
    Liraglutide
    Outcome
    IncreaseOdds of double or triple composite outcome
    Study

    n: not reported in source

    Comparator
    Insulin glargine U100 (DUAL V)
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    The odds of achieving double or triple composite outcomes were significantly higher for IDegLira versus IGlar U100 or basal-bolus for all 3 HbA1c targets (P < 0.0001 in each case) in both trials.
    2 context sentences
    Summary · context
    Proportions of patients achieving HbA1c targets (< 7.5%, < 8.0%, and ≤ 9.0%) by the end of trial were assessed via 3 outcomes: alone, without either hypoglycemia or weight gain (double composite outcome), or without a combination of hypoglycemia and weight gain (triple composite outcome).
    Summary · context
    This is a post hoc analysis of the DUAL V and DUAL VII 26-week trials, which randomized patients with T2D uncontrolled (HbA1c 7%-10%) on insulin glargine 100 units/mL (IGlar U100) and metformin to IDegLira or continued IGlar U100 titration (DUAL V) or IGlar U100 + insulin aspart (DUAL VII), all with metformin.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  6. 06HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, the odds of reaching HbA1c targets without hypoglycaemia or weight gain were significantly higher with the fixed-dose combination IDegLira than with basal-bolus therapy.

    In plain wordsIn adults with type 2 diabetes, insulin degludec/liraglutide gave higher odds than basal-bolus insulin of reaching HbA1c targets without low sugar or weight gain.

    Peptide
    Liraglutide
    Outcome
    IncreaseOdds of double or triple composite outcome
    Study

    n: not reported in source

    Comparator
    Basal-bolus therapy (DUAL VII)
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    The odds of achieving double or triple composite outcomes were significantly higher for IDegLira versus IGlar U100 or basal-bolus for all 3 HbA1c targets (P < 0.0001 in each case) in both trials.
    2 context sentences
    Summary · context
    Proportions of patients achieving HbA1c targets (< 7.5%, < 8.0%, and ≤ 9.0%) by the end of trial were assessed via 3 outcomes: alone, without either hypoglycemia or weight gain (double composite outcome), or without a combination of hypoglycemia and weight gain (triple composite outcome).
    Summary · context
    This is a post hoc analysis of the DUAL V and DUAL VII 26-week trials, which randomized patients with T2D uncontrolled (HbA1c 7%-10%) on insulin glargine 100 units/mL (IGlar U100) and metformin to IDegLira or continued IGlar U100 titration (DUAL V) or IGlar U100 + insulin aspart (DUAL VII), all with metformin.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  7. 07HumanNot a test of Liraglutide aloneRandomized controlled trialOther

    In a US payer analysis in adults with type 2 diabetes, the annual cost per patient reaching HbA1c targets without hypoglycaemia and weight gain was lower with the fixed-dose combination IDegLira than with insulin glargine U100.

    In plain wordsIn a US cost analysis in adults with type 2 diabetes, the insulin degludec/liraglutide combination cost less per person reaching targets than insulin glargine.

    Peptide
    Liraglutide
    Outcome
    Not applicableAnnual cost per patient reaching HbA1c targets without hypoglycaemia and weight gain
    Study

    n: not reported in source

    Comparator
    Insulin glargine U100 (DUAL V)
    Outcome group
    Cost-effectiveness · Whole body

    Source sentences

    Summary
    For each $1 spent on IDegLira, the equivalent annual costs per patient to achieve HbA1c targets of < 7.5%, < 8.0%, or ≤ 9.0% without hypoglycemia and without weight gain were $2.43, $2.10, and $2.05, respectively, for IGlar U100 and $6.33, $5.80, and $6.06, respectively, for basal-bolus therapy.
    2 context sentences
    Summary · context
    This short-term (1-year) cost-effectiveness analysis was conducted from the perspective of a U.S. health care payer.
    Summary · context
    This is a post hoc analysis of the DUAL V and DUAL VII 26-week trials, which randomized patients with T2D uncontrolled (HbA1c 7%-10%) on insulin glargine 100 units/mL (IGlar U100) and metformin to IDegLira or continued IGlar U100 titration (DUAL V) or IGlar U100 + insulin aspart (DUAL VII), all with metformin.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  8. 08HumanNot a test of Liraglutide aloneRandomized controlled trialOther

    In a US payer analysis in adults with type 2 diabetes, the annual cost per patient reaching HbA1c targets without hypoglycaemia and weight gain was lower with the fixed-dose combination IDegLira than with basal-bolus therapy.

    In plain wordsIn a US cost analysis in adults with type 2 diabetes, the insulin degludec/liraglutide combination cost less per person reaching targets than basal-bolus insulin.

    Peptide
    Liraglutide
    Outcome
    Not applicableAnnual cost per patient reaching HbA1c targets without hypoglycaemia and weight gain
    Study

    n: not reported in source

    Comparator
    Basal-bolus therapy (DUAL VII)
    Outcome group
    Cost-effectiveness · Whole body

    Source sentences

    Summary
    For each $1 spent on IDegLira, the equivalent annual costs per patient to achieve HbA1c targets of < 7.5%, < 8.0%, or ≤ 9.0% without hypoglycemia and without weight gain were $2.43, $2.10, and $2.05, respectively, for IGlar U100 and $6.33, $5.80, and $6.06, respectively, for basal-bolus therapy.
    2 context sentences
    Summary · context
    This short-term (1-year) cost-effectiveness analysis was conducted from the perspective of a U.S. health care payer.
    Summary · context
    This is a post hoc analysis of the DUAL V and DUAL VII 26-week trials, which randomized patients with T2D uncontrolled (HbA1c 7%-10%) on insulin glargine 100 units/mL (IGlar U100) and metformin to IDegLira or continued IGlar U100 titration (DUAL V) or IGlar U100 + insulin aspart (DUAL VII), all with metformin.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.